Topiramate Shows Promise in Reducing PTSD Symptoms
A recent study investigated the efficacy and safety of topiramate monotherapy in treating civilian posttraumatic stress disorder (PTSD). The study was a double-blind, placebo-controlled trial involving outpatients aged between 18 and 64 years.
- The study involved outpatients aged between 18 and 64 years with DSM-IV non-combat-related PTSD.
- Participants were required to have Clinician-Administered PTSD Scale (CAPS) scores of 50 or higher.
- Topiramate was started at 25 mg/day and titrated by 25-50 mg/week to 400 mg/day or maximum tolerated dose.
- Data were collected between April 26, 2002, and February 4, 2004.
- The intent-to-treat (ITT) population comprised 38 patients with mean baseline total CAPS scores of 88.3 (topiramate, N = 19) and 91.1 (placebo, N = 19).
- Although a decrease in total CAPS score was noted (topiramate, -52.7; placebo, -42.0), this difference was not statistically significant (p = .232).
- Topiramate-treated patients exhibited significant reductions in reexperiencing symptoms (CAPS cluster B: topiramate, 74.9%; placebo, 50.2%; p = .038) and Treatment Outcome PTSD scale (topiramate, 68.0%; placebo, 41.6%; p = .025).
According to the National Institute of Mental Health, about 3.6% of US adults had PTSD in the past year.
More on Topiramate